Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
It is clear and predictable, we need funds and this has been happen many times before at the same way.
Not insulting, price is the only question and we will see it tomorrow/on Monday.
Some delays and not delivered favorable results for Traumakine, but it is ok also taking into account what is going on in hospitals' due to the Covid issues.
Let's see when and what milestones will be reported.
I'll stay positive, however shareholder value is creating rather slowly still.
I think we are much undervaluated now. However, we are still in the phase 2 (and only with solid tumors) and this is rather long path to the market.
I do not doubt we have invention, most likely as industry disruptor.
It will take time. Will require money, ca 20m$ per phase 3.
We have many 10% dilution ahead. Even with partnering (too early IMO now) we are still in the middle of nowhere.
There is no specific PR needed today. Markku is wise and I hope he will make right decisions. He has experience and has also prominent friends in academia and global biotech industry.
Traumakine is different story, might qualify to the market much sooner than bex.
Patience is the key.
£50 could be great target, better £25 because of diluting during the road.
Moving SP higher in earlier stage => less dilution.
OK. Something to consider. This is 1000bn industry.
Industry disruptor in oncology could be worth also 10-20bn. Not sure yet we will be. Not sure what current owners will vote if £1bn on the table. However, this case = sky is the limit. For humanity, for people who suffering. Faron has made and is making great work IMO.
It will be easily 10bn+ valuation for big pharma. If it is that big.
And it seems possible that we may get market approval in US before 3rd phase is ended.
However, this is highly speculative and first, it should be industry disruption, not just one step ahead.
First we will see Nobel prize within 3 years...
Story is too sweet to believe, but let's see.
Traumakine is not the first and not the only ARDS treatment funded by DoD.
And once again. I hope Faron will succeed. We all will be happy then. Those days, in US biotechs' market , are crazy enough to not be listed there. Costs to comply with US accounting standards and potential shorting is not for Faron. LSE and Helsinki is enough for us. This is my message. Please stay away from the US financial markets. Still see 2bn market cap possible after phase 2 success. They will not let Traumakine to the market that easy. Could save hundreds of thousand lives in Covid-19. IDK why. There are more treatments for ARDS research supported by DoD.
Please read once more. $AKBA has completed 3rd phase. However, you missed the point. In US, everything is slaughtered now. No one is expecting something from a Finnish biotech in those days. I really hope Faron will succeed. Btw. $FGEN guy is well known by Markku? This is real concern for me.
Well,
looking for recent developments in US markets, small biotech's, I would like to say that maybe there is no positive added value to Faron related with US listing.
I've seen companies with finished and successful Phase 3 and with remarkable results in Phase 2, oncology-related, really slaugthered during last months.
If markets will remain volatile, there is no good news for companies like Faron, who has permanently to dilute in small amount to finance trials.
Entering to bex phase 3, we will need significant financing and I think Europe might be better financial market to get funding.
Listing after funding phase 3 is different case.
Timing is important and I'll consider Faron too risky for me if listed in US before we have cards on the table with bex phase 3.
GLA.
IMO we may have one or serveral Traumakine updates in this or coming weeks.
I also consider potential option for small/moderate placement as we had in January.
No of cohorts rising, Traumakine commercialization will need additional funding.
If they are wise enough they have to rise monthly average for placement pricing.
This is personally my speculation, gut feeling. Do not take it too seriously.
I hope there will be no takeover needed.
They are that effective in the cost management and so much work with Traumakine is already done that IMO they need very little dilution to finalize successfully Bexmarilimab studies.
Another story. Last nights, studing new Covid-19 treatmet options, I understood how valuable our Interferon patents are, if someone will start to develop inhalated powders... And sooner or later, IV IFN Beta will be needed to the market.
This is great set with two clinical stage success stories and some ideas already in preclinical.
Wish you nice week!
@Limest0ne, look at cancer plays in Nasdaq. I am not sure this volatility is something we will like, but ATM offerings are much easier to arrange if additional funding is needed. Look at $HTBX. Last couple of months. Crazy. US brings financing options with extremely high volatility. But, market is there and FDA is there.
Well. Coming week is much better for any PR. Now it is clear that until last Wednesday, there was globally large sell-off by institutionals from biotechs (more than 50 bnUSD). Bleeding in Helsinki was that times not by Lago dumping to the market, but by non-local financial houses. Steady selling, weeks. I think our valuation will soon be re-rated back to over 4ish. With the PR, it will depend. Stimulus passed yesterday, two stamps more needed, but market will likely take it as granted tomorrow. Looking forward for a bright week overall.